VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 5, 2014) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE:APC) has been preparing several series of potential anticancer agents, each of which has its own individual attributes for drug development as novel proprietary agents.
These agents represent modifications of the natural parent protein which itself has been demonstrated to retard tumor growth and overcome the immune system's tolerance of cancer cells, which allows them to grow and proliferate.
The goal of APC's program is to exploit the baseline activity of the parent protein through its protein modification technologies, by improving its activity and adding additional functions which retard tumor growth through multiple mechanisms.
We recently reported in our press release of January 28, 2014 that members of the first series, which have been selected for further testing in animal models of cancer, have demonstrated statistically significant retardation of tumor growth in mice and have affinity for specific cancer cells.
We are now especially pleased to report that in the first detailed studies with our collaborators, the lead member of the first series has exhibited stunning activity in retarding tumor growth in mice, substantially superior to the parent protein. The experiments were performed by varying the concentration of the modified protein, which gave classical dose-dependent plots showing retardation of tumor growth. Alexander (Allen) Krantz stated "that these studies substantiate our earlier findings that our chemical modifications to the protein, enhance the anticancer activity of the unmodified protein, and provide compelling support for our strategies designed ultimately to achieve therapeutic benefits for the Company's proprietary molecular assets. It is particularly gratifying that the results of testing our first lead molecule in mice have exceeded our high expectations for this series and is currently our gold standard."
Preliminary results with members of the second series indicate that they also exhibit high affinity for specific cancer cells. They will be advanced for further testing in animals to accelerate our quest for compelling clinical candidates that will provide a basis for deal-making with industrial partners."
About APC
APC has been applying its Foundation Trinity™ Technology to proteins targeted for the treatment of cancers. Advanced targeted therapies are designed to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics' market in the near future. The Company's goals are not only to employ therapy targeted for tumor cells, but also to deliver combination therapy in a single, pure therapeutic agent. To achieve this end, it has been the Company's intention to utilize a unique protein (and related systems), not only as a delivery vehicle to tumor cells, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein surface - both key to efficient manufacturing and product development. The protein vehicle has emerged as a potential immunotherapeutic as it is implicated in activating the immune system to attack and help clear tumor cells. Immunotherapy is perhaps the most powerful current approach to cancer, and one of great commercial interest to the pharmaceutical industry.
ON BEHALF OF THE BOARD
Alexander (Allen) Krantz, President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.
Contact Information:
(617) 638-0340
www.advancedproteome.com